Who
Bruce Booth
Director
Company insider
Files Form 4 as: Director, Kymera Therapeutics; Director, Sionna Therapeutics; Director, Vigil Neuroscience; Director, Tectonic Therapeutic; Director, Dianthus Therapeutics; Director, Cogent Biosciences; Director, Viridian Therapeutics; Director and 10% owner, Larimar Therapeutics.
In numbers
- Trades disclosed
- 562
- Buys
- 6
- Sells
- 52
- Bought
- $37.7M
- Sold
- $549.9M
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 24 Jun 2014
- Last trade
- 29 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $587K5,549 at $105.78 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $291K2,698 at $107.76 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $162K1,498 at $108.28 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $121K1,104 at $109.75 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $119K1,078 at $110.67 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K130 at $111.20 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M14,798 at $106.63 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.1M19,419 at $107.76 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.2M10,848 at $108.28 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $874K7,968 at $109.75 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $855K7,723 at $110.67 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $104K934 at $111.20 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $81K770 at $105.78 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $227K2,133 at $106.63 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $587K5,549 at $105.78 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M14,798 at $106.63 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.1M19,419 at $107.76 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.2M10,848 at $108.28 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $874K7,968 at $109.75 | filing |
| 29 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $855K7,723 at $110.67 | filing |
The newest 500 lines are listed; the numbers count every line.
News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)KYMR · prnewswire.com · 12 Oct 2026
0 headlines in the last 90 days name Bruce Booth; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.